GLPwatch
Acute Pancreatitis in a Patient Taking Semaglutide.
Cureus · 2023
Last updated 2026-09-03A case study reports acute pancreatitis in a patient who had recently started taking semaglutide, a GLP-1 drug, for type 2 diabetes. While a large trial found no increased risk of pancreatitis with semaglutide, some studies suggest it may still cause pancreatic inflammation. The report advises clinicians to be aware of this possible side effect as more people use GLP-1 drugs.
AI summary of the abstract below.
| Journal | Cureus, 2023 |
|---|---|
| Citations | 17 |
| Relative citation ratio | 1.85 |
| NIH percentile | 71 |
| Molecules | semaglutide |
Abstract
The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. Though recent evidence suggests no increased risk of acute pancreatitis (AP) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with GLP-1 RAs. We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes. As GLP-1 RA use increases, clinicians should be aware of their potential to cause acute pancreatitis.
Verbatim abstract via PubMed 37731423 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.